Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Normal human bronchial epithelial cell Next Gen sequencing (RNA-seq) for differential gene expression of untreated versus IL4 or IL4+ALOX15 siRNA treated cells

ABSTRACT: Normal human bronchial epithelial cell Next Gen sequencing (RNA-seq) for differential gene expression of untreated versus IL4 or IL4+ALOX15 siRNA treated cells

PROVIDER: PRJNA743661 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15037902_1.fastq.gz	Fastqsanger.gz
	SRR15037902_2.fastq.gz	Fastqsanger.gz
	SRR15037903_1.fastq.gz	Fastqsanger.gz
	SRR15037903_2.fastq.gz	Fastqsanger.gz
	SRR15037904_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 36

Similar Datasets

Normal human bronchial epithelial cell Next Gen sequencing (RNA-seq) for differential gene expression of untreated versus IL4 or IL4+ALOX15 siRNA treated cells

Project description:Purpose: Identify genes regulated by ALOX15 in Normal human bronchial epithelial (NHBE) cells that were treated with +/- IL4 and +/- ALOX15 siRNA by Next-gen sequencing

2024-04-03 | GSE179420 | GEO

A549 cell Next Gen sequencing (RNA-seq) for differential gene expression of untreated versus IL4 or IL4+ALOX15 siRNA treated cells

Project description:Purpose: Identify genes regulated by ALOX15 in A549 cells that were treated with +/- IL4 and +/- ALOX15 siRNA by Next-gen sequencing

2024-04-03 | GSE171750 | GEO

A549 cell Next Gen sequencing (RNA-seq) for differential gene expression of untreated versus IL4 or IL4+ALOX15 siRNA treated cells

Project description:A549 cell Next Gen sequencing (RNA-seq) for differential gene expression of untreated versus IL4 or IL4+ALOX15 siRNA treated cells

| PRJNA720719 | ENA

Segmental Bronchial Allergen Challenge Elicits Distinct Metabolic Phenotypes in Allergic Asthma

Project description:Asthma is a complex syndrome associated with episodic decompensations provoked by aeroaller-gen exposures. The underlying pathophysiological states driving exacerbations are latent in the resting state and do not adequately inform biomarker-driven therapy. A better understanding of the pathophysiological pathways driving allergic exacerbations is needed. We hypothesized that disease-associated pathways could be identified in humans by unbiased metabolomics of bron-choalveolar fluid (BALF) during the peak inflammatory response provoked by a bronchial aller-gen challenge. We analyzed BALF metabolites in samples from 12 volunteers who underwent segmental bronchial antigen provocation (SBP-Ag). Metabolites were quantified using liquid chromatography-tandem mass spectrometry (LC–MS/MS) followed by pathway analysis and cor-relation with airway inflammation. SBP-Ag induced statistically significant changes in 549 fea-tures that mapped to 72 uniquely identified metabolites. From these features, two distinct induci-ble metabolic phenotypes were identified by the principal component analysis, partitioning around medoids (PAM) and k-means clustering. Ten index metabolites were identified that in-formed the presence of asthma-relevant pathways, including unsaturated fatty acid produc-tion/metabolism, mitochondrial beta oxidation of unsaturated fatty acid, and bile acid metabolism. Pathways were validated using proteomics in eosinophils. A segmental bronchial allergen chal-lenge induces distinct metabolic responses in humans, providing insight into pathogenic and pro-tective endotypes in allergic asthma.

2022-06-09 | PXD033172 | Pride

RNA aptamers specific for IL4-treated MSC2 cell line

Project description:We performed an unsupervised, high-throughput (HT) sequencing-cell SELEX (systematic evolution of ligands by exponential enrichment) using the MDSC-derived cell line MSC2. Specifically untreated MSC2 and IL4 treated MSC2 were used as negative and positive selector respectively. Selection was started from a 5 ug of 40bp variable region linked to two constant region.

2020-06-21 | GSE113378 | GEO

Alcanivorax sp. IL4

Project description:Alcanivorax sp. IL4 Genome sequencing

| PRJNA161065 | ENA

lắp ráp bộ gen

Project description:lắp ráp bộ gen

| PRJEB32156 | ENA

Emodin inhibits macrophage alernative activation [Control-IL4-Emodin]

Project description:In order to fully characterize emodin's effects on macrophage alternative activation, peritoneal macrophages were stimulated with IL4 with or without emodin and gene expression was analyzed using a whole genome microarray. Emodin significantly attenuated the IL4 induced changes in a large percentage of genes (60%) through inhibiting multiple signaling pathways. RT-qPCR was used to confirm the results in several genes associated with M2 macrophage activation including: Arg1, Chi3l3, and CD206. Three-condition, one-color experiment: Vehicle control, IL4 or IL4-Emodin treated periferal WBC PMN samples: 4 biological replicates each.

2016-07-04 | E-GEOD-73309 | biostudies-arrayexpress

B cell response to CD40 and IL4 treatment

Project description:Temporal analysis (60, 180, 360 min) of B cells treated with CD40 alone, IL4 alone or CD40 and IL4 (all in triplicates). Keywords: other

2004-02-13 | GSE1023 | GEO

IL4 promotes phagocytosis of murine leukemia cells counteracted by CD47 upregulation

Project description:Cytokines are key regulators of tumor immune surveillance by controlling immune cell activity. Here, we investigated whether interleukin 4 (IL4) has antileukemic activity via immune-mediated mechanisms in an in vivo murine model of acute myeloid leukemia driven by the MLL-AF9 fusion gene. Although IL4 strongly inhibited leukemia development in immunocompetent mice, the effect was diminished in immune-deficient recipient mice, demonstrating that the antileukemic effect of IL4 in vivo is dependent on the host immune system. Using flow cytometric analysis and immunohistochemistry, we revealed that the antileukemic effect of IL4 coincided with an expansion of F4/80+ macrophages in the bone marrow and spleen. To elucidate whether this macrophage expansion was responsible of the antileukemic effect, we depleted macrophages in vivo with clodronate liposomes. Macrophage depletion eliminated the antileukemic effect of IL4, showing that macrophages mediated the IL4-induced killing of leukemia cells. In addition, IL4 enhanced murine macrophage-mediated phagocytosis of leukemia cells in vitro. Global transcriptomic analysis of macrophages revealed an enrichment of signatures associated with alternatively activated macrophages and increased phagocytosis upon IL4 stimulation. Notably, IL4 concurrently induced Stat6-dependent upregulation of CD47 on leukemia cells, which suppressed macrophage activity. Consistent with this finding, combining CD47 blockade with IL4 stimulation enhanced macrophage-mediated phagocytosis of leukemia cells. Thus, IL4 has two counteracting roles in regulating phagocytosis in mice; enhancing macrophage-mediated killing of leukemia cells, but also inducing CD47 expression that protects target cells from excessive phagocytosis. Taken together, our data suggests that combined strategies that activate macrophages and block CD47 have therapeutic potential in AML.

2021-07-14 | GSE155048 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data